CLNN News and Press, Clene Inc. From 09/25/23

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. are reporting on long-term follow-up data for participants in the HEALEY ALS Platform Trial; patients in the study were treated with CNM-Au8(R) 30mg for up to 133 weeks. According to the announcement, data from 59 patie...

Prolonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8 ® 30mg compared to PRO-ACT matched placebo over long-term follow-up, p=0.046 Prolonged life with 59% decreased risk of death for participants in an integrate...

2023-09-22 16:31:05 ET More on Clene Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene For further details see: Clene files prospectus related to issuance, offer and resale of up to 3M shares

2023-09-11 11:50:59 ET Clene ( NASDAQ: CLNN ) rises 5.2% after the company's disclosure on Sept. 8 that former director Chidozie Ugwumba now owns ~19.9% in the biopharmaceutical firm. Ugwumba owns 28.02 million shares in the company. For further details see: ...

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuron...

19.3 month significant survival difference for CNM-Au8 ® treated participants versus placebo 52% significant decreased risk of ALS clinical worsening events Over 475 years of CNM-Au 8 treatment exposure without any identified safety signals SALT LAKE C...

2023-08-14 12:53:38 ET Clene press release ( NASDAQ: CLNN ): Q2 GAAP EPS of -$0.29 misses by $0.17 . Revenue of $0.27M beats by $0.16M . For further details see: Clene GAAP EPS of -$0.29 misses by $0.17, revenue of $0.27M beats by $0.16M

Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients treated with CNM-Au8 ® in the HEALEY ALS Platform trial Announced publication of the results of the Phase 2 RESCUE ALS study and i...

SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseas...

2023-06-29 13:20:47 ET Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure. Today, we’re exploring the territory of cheap stocks trading under $1. What are Penny Stocks? Penny stocks typicall...